NEW YORK, January 26, 2021 - Q BioMed Inc. (OTCQB: QBIO), announces that it has received additional notices of patent allowances from both Canada and Japan for its Uttroside-B molecule intended to treat liver cancer. The patent titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma” is a Method Of Use patent that covers the use of Uttroside-B for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer. International and additional U.S. claims are currently under prosecution for the technology which addresses a severe unmet need for a safe and effective drug to treat HCC.

Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India and the Oklahoma Medical Research Foundation.

“The additional jurisdictions in which we now have patent allowance further ensures the IP protection for what could be a significant chemotherapeutic agent for the treatment of liver cancer around the globe. We expect to initiate our first preclinical tests and anticipate preparing Uttroside-B for an investigational new drug (IND) application with the U.S. FDA before year end,” stated Q BioMed CEO Denis Corin.

Uttroside-B has shown ten times the potency against HCC as compared to the current standard of care drug in early pre-clinical investigation. Currently, there are only two approved first-line therapies for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs. An estimated 700,000 people are diagnosed with HCC each year, with the global market for liver cancer drugs expected to grow to $3.9 billion by 2027.

About Q BioMed Inc.

Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit http://www.QBioMed.com and sign up for regular updates.

Q BioMed Media Contact:
Denis Corin
CEO

Investor Relations:
Keith Pinder
+1(404) 995-6671
This email address is being protected from spambots. You need JavaScript enabled to view it.

Forward-Looking Statements:

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.